Kenvue Inc. (KVUE)
About Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $15.1B
- Net income
- $1.5B
- Total assets
- $27.1B
- Market cap
- $34.0B
- Gross margin
- 58.1%
- Operating margin
- 16.0%
- Net margin
- 9.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $15.1B
- Cost of revenue
- $6.3B
- Gross profit
- $8.8B
- Operating expenses
- $6.4B
- Operating income
- $2.4B
- Income tax
- $529.0M
- Net income
- $1.5B
- EPS (basic)
- $0.77
- EPS (diluted)
- $0.76
Balance sheet
- Total assets
- $27.1B
- Current assets
- $5.7B
- Total liabilities
- $16.3B
- Current liabilities
- $5.9B
- Shareholders’ equity
- $10.8B
Cash flow
- Operating cash flow
- $2.2B
- Investing cash flow
- -$436.0M
- Financing cash flow
- -$1.8B
- Net cash flow
- -$8.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $34.0B
- P/E ratio
- 25.4
- EPS (diluted)
- $0.76
- Dividend yield
- 4.3%
- Shares outstanding
- 1.8B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 4, 2023
Kenvue Inc. (KVUE) Stock Price
- Profitable — net income of $1.5B in FY2025.
- Revenue declined 2% from FY2023 to FY2025.
- Gross margin of 58.1%, net margin 9.7%.
- Trading 16% below its 52-week high.
- Pays a dividend yielding about 4.3% annually.
- Valued at a price-to-earnings (P/E) ratio of 25.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Kenvue Inc..
Write a review
News about Kenvue Inc.
News & sentiment via Polygon.io
Kenvue Inc.: frequently asked questions
Is Kenvue Inc. an American company?
Yes — Kenvue Inc. is an American company headquartered in Summit, New Jersey. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Kenvue Inc. headquartered?
Kenvue Inc. is headquartered in Summit, New Jersey, United States.
Is Kenvue Inc. publicly traded?
Yes — Kenvue Inc. is a publicly traded company. Its stock trades under the ticker symbol KVUE on the NYSE.
What does Kenvue Inc. do?
Kenvue Inc. is an American Cosmetics company in the Health & Beauty sector.
